Chemoproteomics and Chemogenomics Methods: Approaches Involving In Vitro Affinity Screening Of Small-Molecule Compounds against Purified Proteins - 'Chemical Genetics in Drug Discovery'.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47212) has announced the addition of Chemical Genetics in Drug Discovery to their offering. In the drive to streamline the drug discovery process, biotechnology and pharmaceutical companies are harnessing chemical genetics as a tool to overcome the limitations of traditional target-based drug discovery. Although chemical genetics approaches show great potential, their ultimate success can be measured only when drug candidates discovered using these technologies reach the marketplace. Questions Answered in This Spectrum Report Although chemical genetics was originally developed for basic biological research, industry has enlisted this approach to improve the effectiveness of small-molecule drug discovery and development. What are the potential advantages of chemical genetics for drug discovery, and how will chemical genetics change the current drug discovery model? What technologies enable its use? Several drug candidates derived from chemical genetics programs are now in the early stages of development, some of which are first-in-class agents that may have been difficult to discover by other means. Which companies are utilizing chemical genetics strategies, and what promising agents are in their pipelines? The NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. has launched an initiative to create a comprehensive set of small-molecule compounds that can modulate To insert a data signal into a carrier wave or direct current. See modulation. human genes and their functions, proving that the scientific community believes that chemical genetics has great potential both in biological research and in drug development. What are the primary aims of the NIH program? How does the program promise to drive innovation in chemical genetics, and what resources will it offer to commercial and academic researchers? Scope: * Basics of chemical genetics: development, key aspects, and the central role of diversity oriented synthesis. * Chemical genetics strategies and tools: simultaneous target and lead discovery, diversity oriented synthesis libraries, chemoproteomics strategies, agonists and reversal of loss-offunction, and enabling technologies for chemical genetics. * The NIH Molecular Libraries Roadmap: Molecular Libraries Screening Center Network, PubChem, technology development, and expectations of the MLR MLR mixed lymphocyte reaction. MLR Myocardial laser revascularization, see there initiative. * Chemical genetics for drug discovery: cellular phenotypic screens, model organisms, and cellular gene expression screens. * Chemoproteomics and chemogenomics methods: approaches involving in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. affinity screening of small-molecule compounds against purified proteins. * Outlook for chemical genetics: the impact of chemical genetics on the drug-discovery programs of pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . Content Outline: Executive Summary Strategic Considerations Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. Implications Introduction to Chemical Genetics: The Chemistry-First Strategy Basics of Chemical Genetics Chemical Genetics Strategies and Tools Simultaneous Target and Lead Discovery Diversity-Oriented Synthesis Libraries Chemoproteomics Strategies Agonists and Reversal of Loss-of-Function Enabling Technologies for Chemical Genetics The NIH Molecular Libraries Roadmap Molecular Libraries Screening Center Network PubChem Technology Development Expectations of the MLR Initiative Chemical Genetics for Drug Discovery Cellular Phenotypic Screens CombinatoRx CGI CGI in full Common Gateway Interface. Specification by which a Web server passes data between itself and an application program. Typically, a Web user will make a request of the Web server, which in turn passes the request to a CGI application program. Pharmaceuticals Synta Pharmaceuticals Model Organisms Cellular Gene Expression Screens Avalon Pharmaceuticals GlaxoSmithKline The Broad Institute Chemoproteomics and Chemogenomics Methods Schering-Plough's Automated Ligand Identification System High-Throughput Kinase Screening at Exelixis and Vertex Ambit (language) AMBIT - Algebraic Manipulation by Identity Translation (also claimed: "Acronym May Be Ignored Totally"). An early pattern-matching language, developed by C. Christensen of Massachusetts Computer Assocs in 1964, aimed at algebraic manipulation. Biosciences' KinomeScan Serenex's Affinity-Based Chemoproteomics Platform Cellzome's Chemical Proteomics Technology Outlook for Chemical Genetics Tables 1. Potential Advantages of Chemical Genetics Strategies and Approaches 2. Enabling Technologies for Chemical Genetics 3. Select Companies Utilizing Cellular or Whole-Organism Phenotypic Screen Technologies for Chemical Genetics 4. Companies Utilizing Chemoproteomics or Chemogenomics Technologies 5. Select Small-Molecule Agents Discovered Using Chemical Genetics Figures 1. Chemical Genetic Strategy to Discover Compounds That Reverse PTEN PTEN Protein Tyrosine Phosphatase PTEN Phosphatase and Tensin Homolog PTEN Prime Time Entertainment Network (television network) Loss-of- Function 2. CGI Pharmaceuticals' Analogue Sensitive Kinase Alleles (ASKA ASKA Anti-Slipknot Army ) Technology Companies Mentioned: Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. Affymetrix Ambit Biosciences Amgen AstraZeneca Avalon Pharmaceuticals Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Broad Institute Cellzome CGI Pharmaceuticals CombinatoRx Exelixis GlaxoSmithKline Infi nity Pharmaceuticals Johnson & Johnson Kosan Biosciences Novartis Pfi zer Sanofi -Aventis Schering-Plough Serenex Synta Pharmaceuticals Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. For more information visit http://www.researchandmarkets.com/reports/c47212 Source: Decision Resources |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion